NCT04940325 - Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

May 12, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2028

Conditions

Metastatic Lung CancerAdvanced Non Small Cell Lung CancerUnresectable Non-small Lung Cancer

Interventions

DRUG

DS-1062a

First infusion for 90 minutes and then infusion duration can be decreased to 30 minutes if participant didn't experience infusion related reactions (IRR)

Trial Locations (9)

14076

Centre François Baclesse, Caen

29200

Institut de Cancérologie, CHRU Morvan de Brest, Brest

33076

Institut Bergonié, Bordeaux

67091

Hôpitaux Universitaires de Strasbourg, Strasbourg

69310

Hospices Civils de Lyon - Centre Hospitalier Lyon Sud, Pierre-Bénite

75014

Hôpital Cochin, Paris

75970

Hôpital Tenon, Paris

94010

Centre Hospitalier Intercommunal de Créteil, Créteil

94805

Gustave Roussy, Villejuif